2009, Clinical Trials, Concentrates and DEA

Search:

DAY

WEEK

MONTH

YEAR

Select your country:
Sign up | Log in

2009

Clinical Trials

Concentrates

DEA

Cannabis Industry Leaders Speak With CLR on Current Delta 8 Issues In The Industry

Cannabis Law Report

JUNE 4, 2021

With Delta 8, one is not going to have an anxious or paranoia episode as can be common for newcomers to marijuana forms of cannabis – especially with high concentration of THC that is readily available today. Born and raised in San Diego, Dave attended San Diego State University in 2009 where he received his bachelor’s degree in chemistry.

Research and Development

Research and Development Seed-To-Sale Cannabinoids THC

Report: “Key pharmacological differences between side effects of refined, pharmaceutical CBD formulations and whole plant extracts:”

Cannabis Law Report

JULY 12, 2019

Recent studies on the effectiveness of cannabidiol in the rare seizure disorders Dravet Syndrome and Lennox-Gastaut syndrome have prompted a biopharmaceutical company to perform clinical trials of its own to bring a cannabidiol based drug to the American market through the process of FDA approval. 2009 July ; 205(1): 171–174.

Extraction

Extraction Pharmaceutical CBD Epilepsy

Medical Cannabis Brief

Cannabis Industry Leaders Speak With CLR on Current Delta 8 Issues In The Industry

Report: “Key pharmacological differences between side effects of refined, pharmaceutical CBD formulations and whole plant extracts:”

Stay Connected